Biocon and Civila Partner 让美国糖尿病患者更容易负担得起Insulin Aspart。 Biocon and Civica partner to make Insulin Aspart more affordable for diabetics in the U.S.

Biocon Biologics and Civilia Inc. 合作增加使用Insulin Aspart的渠道。 在美国,Insulin Aspart是一个快速反应的胰岛素,Biocon公司将向Ciciana供应该药物,后者将在临床试验后制造该药物并将之商业化。 Biocon Biologics and Civica, Inc. have teamed up to increase access to Insulin Aspart, a rapid-acting insulin, in the U.S. Biocon will supply the drug substance to Civica, who will manufacture and commercialize it after clinical trials. 这项合作旨在使3 840万患糖尿病的美国人更能负担得起胰岛素。 This collaboration aims to make insulin more affordable for the 38.4 million Americans with diabetes. 生物con公司本身的Insulin Aspart产品也正在接受林业发展局的审查。 Biocon's own Insulin Aspart product is also under FDA review.